Azienda Unita Sanitaria Locale Di Modena — Clinical Trial Site

14 Registered trials

8 Currently recruiting

Organisation

Azienda Unita Sanitaria Locale Di Modena

Location

Carpi, Italy

Identifier

ORG-100011203

Address

Via Guido Molinari 1, 41012, Italy

Departments

Ginecologia e Ostetricia
Internal Medicine
Medical Oncology
Medicina Interna e Riabilitativa
Oncologia
Oncologia di prossimità
Oncologia e Oncoematologia
Oncology
UO Gastroentrologia ed Endoscopia Digestiva
UO Medicina Oncologica
UO Oncologia
UOC Medicina Oncologica - Ospedale Ramazzini di Carpi AUSL Modena + DH Ospedale di Mirandola
Urology Unit

Clinical trials at this site (14)

Search interface

Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending

2024-519655-28-00 Premenopausal patients with high-risk HR-positive/HER2- 5
A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K in… Recruiting

2022-501152-28-00 Breast Cancer 4 2022-12-21
PeRinatal Outcomes with ACTive versus expectant management of women with Pre-labor Rupture Of Membranes: a phase III, open-label, randomized… Recruiting

2024-517504-11-00 Pregnant patients diagnosed with premature rupture of m 5 2025-01-29
Continued PD-L1 inhibition with atezolizumab with rechallenge chemotherapy in patients with sensitive relapse SCLC progressing on first-line… Recruiting

2024-511945-20-00 patients affected by small cell lung cancer (SCLC) 4 2025-01-24
PROSPECTIVE EVALUATION OF THE DDR GENES ALTERATION TO PREDICT RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED UROTHELIAL CANCER Recruiting

2024-516450-21-00 metastatic or locally advanced urothelial cancer 6 2024-12-31
MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, … Recruiting

2024-516839-27-00 BRCA wild-type advanced ovarian, fallopian tube and pri 4 2024-12-09
Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3) Recruiting

2022-500587-35-01 Stroke 5 2023-07-06
Efficacy and safety of the combination of Cisplatin plus Nab-paclitaxel and Nivolumab with radiotherapy after maximal tumor resection in non… Recruiting

2024-518937-26-00 Patients with non-metastatic muscle invasive bladder ca 4 2023-02-21
RAndomized, open label, multicenter study of Docetaxel versus an Androgen Receptor-targeted agent (abiraterone orenzalutamide) as first-line… Recruiting

2024-518623-30-00 metastatic castration resistant prostate cancer without 6 2020-10-01
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (M… Ended

2023-507188-21-00 Muscle-Invasive Urothelial Carcinoma (MIBC) of the Blad 5 2021-04-20
A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly sympto… Ended

2023-510453-41-00 Castration resistant prostate cancer patients metastati 5 2015-10-26
A phase III, international, multiCenter, randomized, paraLlel-group, Endoscopist-blinded non-inferiority study of the efficAcy, safety and p… Ended

2025-521451-23-00 Subjects scheduled for elective colonoscopy performed a 5 2025-09-03
A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Mu… Ended

2023-507189-17-00 Muscle-Invasive Urothelial Carcinoma of the Bladder 4 2022-01-09
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab (A-Brave) Ended

2024-514515-10-00 Breast Cancer 5 2016-06-16